Document is current
Any future updates will be listed below
-
Authors
Pascual, Fernando
Au, Carmen
Chikwari, Chido Dziva
Daram, Pierre
Deal, Carolyn
Miranda, Angelica Espinosa
Grad, Yonatan H.
Hook, Edward WIII
Kittiyaowamarn, Rossaphorn
Luckey, Alison
Low, Nicola
Maseko, Venessa
Peters, Remco P. H.
Roberts, Teri
Unemo, Magnus
Srinivasan, Subasree
-
Funding
Funding for this research was provided by:
Governments of Germany, the Netherlands and the United Kingdom
- License Information
-
More Information
Article History
Received: 16 April 2024
Accepted: 25 July 2024
First Online: 3 September 2024
Declarations
:
: Not applicable.
: Not applicable.
: Zoliflodacin is co-developed by the Global Antibiotic Research & Development Partnership (GARDP) in collaboration with Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (Nasdaq: INVA). CA, AL, PD, SS, TR and FP are employees of GARDP. GARDP covered the expenses for RK. CD, HE, RK and MU have participated in zoliflodacin development. The remaining authors declare that they have no competing interests.
